首页> 外文期刊>Trials >Sjogren’s syndrome in clinical trials of traditional Chinese medicine: protocol for the development of a core outcome set
【24h】

Sjogren’s syndrome in clinical trials of traditional Chinese medicine: protocol for the development of a core outcome set

机译:中医临床试验中的Sjogren综合征:核心成果开发的议定书

获取原文
           

摘要

Sjogren’s syndrome (SS) is a chronic autoimmune rheumatic disease with an incidence of 0.03 to 0.3%. In recent years, there are an increasing number of randomized controlled trials of traditional Chinese medicine (TCM) for SS. However, there are generally some problems in these published clinical trials: lack of reporting primary or long-term outcomes and the heterogeneous in different clinical trials’ outcome. Our study aims to determine the priority outcomes and standard TCM syndromes for all stakeholders and reach agreement on the COS and syndromes to be measured and reported in all future TCM trials in patients with SS. A phase-wise refinement approach will be used, consisting of three phases, yet complementary, sub-work phases, whereby each phase will inform the next coming phases. The following are the three phases: (I-a) identifying of a long initial list of outcomes through systematic literature review and semi-structured qualitative interviews and (I-b) identifying an initial list of TCM syndromes through (1) systematic literature review, (2) referencing ancient Chinese medical books, and (3) retrospective studies of medical records; (II) prioritization of outcomes using Delphi survey with different stakeholders, such as health professionals and patients; and (III) through consensus meetings with patients and professionals to agree on the final COS and TCM syndromes. We summarized the actions of COS into three points: direct action, indirect action, and final action. After the final COSs is completed, we will publish this research in a journal to promote communication. Core Outcome Measures in Effectiveness Trials Initiative (COMET) number 1429 . Registered on 01 December 2019.
机译:Sjogren的综合征(SS)是一种慢性自身免疫性风湿病,发病率为0.03〜0.3%。近年来,SS的中药(TCM)的随机对照试验越来越多。然而,这些公布的临床试验中通常存在一些问题:缺乏报告的主要或长期结果以及不同临床试验结果的异质。我们的研究旨在确定所有利益攸关方的优先事项和标准中医综合征,并在SS患者中的所有未来中医试验中达到COS和综合征的达成协议。将使用相位明智的细化方法,包括三个阶段,但互补,子工作阶段,其中每个阶段将通知下一个阶段。以下是三个阶段:(ia)通过系统文献综述和半结构性的定性访谈和(IB)识别通过(1)系统文献综述的中医综合征的初始列表,(2)参考古代医药书籍,(3)医疗记录的回顾性研究; (ii)利用不同利益攸关方使用Delphi调查的结果优先考虑,例如卫生专业人员和患者; (iii)通过与患者和专业人士的共识会议,以达成决定的COS和中医综合征。我们将COS的行为归纳为三点:直接行动,间接行动和最终行动。在最终蜂巢完成后,我们将在促进沟通期刊上发布这项研究。有效性试验倡议(COMET)编号1429的核心结果措施。 2019年12月1日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号